Subpopulations of spore-like cells and uses thereof
Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.
1. A composition comprising a sub-population of spore-like cells expressing one or more markers selected from the group consisting of zinc finger protein 296 (Zfp296), cryptic family protein 1B (crypto), growth differentiation factor-3 (Gdf3), undifferentiated embryonic cell transcription factor 1 (UtF1), embryonic stem cell associated transcript 1 (Ecat1), embryonic stem cell-specific gene 1 (Esg1), sex determining region Y-box 2 (Sox2), paired box protein 6 (Pax6), stem cell antigen 1 (SCA-1), cluster of differentiation protein 29 (CD29), cluster of differentiation protein 34 (CD34), cluster of differentiation protein 90 (CD90), B1 integrin, tyrosine-protein kinase (cKit), surfactant protein C (SP-C), Clara cell 10 protein (CC10), splicing factor 1 (SF1), dosage-sensitive sex reversal gene 1 (DAX1), and superior cervical ganglion-10 protein (SCG10),
in a carrier,
wherein the cells are obtained by a process comprising isolating a viable population of spore-like cells from mammalian tissue or cell containing fluid following oxygen deprivation for at least four hours and culturing the cell in basic media for a time effective for expression of the one or more markers.
2. The composition of claim 1 , wherein the carrier comprises a physiological buffer.
3. The composition of claim 1 , wherein the carrier comprises a hydrogel.
4. The composition of claim 1 , further comprising a biocompatible support structure.
5. The composition of claim 4 , wherein the support structure is selected from the group consisting of a sponge, foam, coral, and a mesh.
6. The composition of claim 1 , wherein the cells further express a gene encoding a protein selected from the group consisting of factor 8, vascular endothelial growth factor and cystic fibrosis transmembrane conductance regulator.
7. A method of treatment, comprising administering the composition of claim 1 to a subject in need thereof.
8. The method of claim 7 , comprising administering the cells within damaged tissue in the subject.
9. The method of claim 8 , wherein the damaged tissue is selected from the group consisting of a burn, a bone fracture, a torn ligament, an atrophied muscle, an ischemic heart and a malfunctioning gland.
10. The method of claim 7 , wherein the cells are administered using a syringe or catheter.